Announcement • Aug 11
Parmax Pharma Limited to Report Q1, 2027 Results on Aug 14, 2026 Parmax Pharma Limited announced that they will report Q1, 2027 results on Aug 14, 2026 Board Change • Jun 15
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Additional Independent Director Ami Shah was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • May 28
Parmax Pharma Limited to Report Q4, 2026 Results on May 30, 2026 Parmax Pharma Limited announced that they will report Q4, 2026 results on May 30, 2026 Announcement • Feb 10
Parmax Pharma Limited to Report Q3, 2026 Results on Feb 14, 2026 Parmax Pharma Limited announced that they will report Q3, 2026 results on Feb 14, 2026 Announcement • Nov 09
Parmax Pharma Limited to Report Q2, 2026 Results on Nov 14, 2025 Parmax Pharma Limited announced that they will report Q2, 2026 results on Nov 14, 2025 Announcement • Sep 08
Parmax Pharma Limited, Annual General Meeting, Sep 30, 2025 Parmax Pharma Limited, Annual General Meeting, Sep 30, 2025, at 15:30 Indian Standard Time. Location: plot no.20,survey no.52,rajkot-, gondal national highway no.27, hadmatala,tal.kotda sangani, dist,rajkot-360311, rajkot India Announcement • Aug 09
Parmax Pharma Limited to Report Q1, 2026 Results on Aug 14, 2025 Parmax Pharma Limited announced that they will report Q1, 2026 results on Aug 14, 2025 Announcement • Jul 02
Parmax Pharma Limited Announces Resignation of Bhakti Aghera as Company Secretary and Compliance Officer (Key Managerial Person), Effective June 30, 2025 Parmax Pharma Limited has announced that Ms. Bhakti Aghera, Company Secretary & Compliance Officer (Key Managerial Person), has resigned from the company with immediate effect due to personal reasons as stated in her resignation letter dated June 30, 2025. The resignation is effective from the close of business hours on June 30, 2025. Announcement • May 21
Parmax Pharma Limited to Report Q4, 2025 Results on May 30, 2025 Parmax Pharma Limited announced that they will report Q4, 2025 results on May 30, 2025 Announcement • Feb 07
Parmax Pharma Limited to Report Q3, 2025 Results on Feb 14, 2025 Parmax Pharma Limited announced that they will report Q3, 2025 results on Feb 14, 2025 New Risk • Feb 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₹178.9m market cap, or US$2.04m). Minor Risk Share price has been volatile over the past 3 months (7.9% average weekly change). Announcement • Nov 06
Parmax Pharma Limited to Report Q2, 2025 Results on Nov 14, 2024 Parmax Pharma Limited announced that they will report Q2, 2025 results on Nov 14, 2024 New Risk • Sep 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$10m (₹175.4m market cap, or US$2.10m). Announcement • Sep 09
Parmax Pharma Limited, Annual General Meeting, Sep 30, 2024 Parmax Pharma Limited, Annual General Meeting, Sep 30, 2024, at 15:00 Indian Standard Time. Location: plot no.20,survey no.52,rajkot-, gondal national highway no.27, hadmatala,tal.kotda sangani, dist,rajkot-360311, rajkot India Announcement • Aug 07
Parmax Pharma Limited to Report Q1, 2025 Results on Aug 14, 2024 Parmax Pharma Limited announced that they will report Q1, 2025 results on Aug 14, 2024 Announcement • May 22
Parmax Pharma Limited to Report Q4, 2024 Results on May 28, 2024 Parmax Pharma Limited announced that they will report Q4, 2024 results on May 28, 2024 Announcement • May 03
Parmax Pharma Limited Appoints Bhakti Aghera as Company Secretary and Compliance Officer, Effective from May 02, 2024 Board of Directors of Parmax Pharma Limited held on 2nd May, 2024, approved by the Board: Appointment of Ms. Bhakti Aghera (Membership No. A68683) as the Company Secretary and Compliance officer of the Company with effect from May 02, 2024. She is an associate member of The Institute of Company Secretaries of India. She has knowledge and experience in corporate legal & secretarial services. Announcement • Jan 31
Parmax Pharma Limited Announces the Resignation of Yash Vora as Company Secretary & Compliance Officer Parmax Pharma Limited announced the resignation of Mr. Yash Vora as Company Secretary & Compliance Officer with effect from 31 January, 2024. Announcement • Aug 16
Parmax Pharma Limited, Annual General Meeting, Sep 29, 2023 Parmax Pharma Limited, Annual General Meeting, Sep 29, 2023, at 15:00 Indian Standard Time. Announcement • Aug 08
Parmax Pharma Limited to Report Q1, 2024 Results on Aug 14, 2023 Parmax Pharma Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Announcement • May 25
Parmax Pharma Limited to Report Q4, 2023 Results on May 30, 2023 Parmax Pharma Limited announced that they will report Q4, 2023 results on May 30, 2023 Announcement • Feb 05
Parmax Pharma Limited to Report Q3, 2023 Results on Feb 11, 2023 Parmax Pharma Limited announced that they will report Q3, 2023 results on Feb 11, 2023 Announcement • Nov 06
Parmax Pharma Limited to Report Q2, 2023 Results on Nov 12, 2022 Parmax Pharma Limited announced that they will report Q2, 2023 results on Nov 12, 2022 Announcement • Sep 09
Parmax Pharma Limited, Annual General Meeting, Sep 30, 2022 Parmax Pharma Limited, Annual General Meeting, Sep 30, 2022, at 14:00 Indian Standard Time. Location: the Registered office of the Company situated at Plot no. 20, survey no. 52 Rajkot-Gondal National Highway no. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot Gujarat India Agenda: To receive, consider and adopt the Audited Balance Sheet as at 31 March 2022, the Audited Statement of Profit and Loss for the year ended on that date and the Reports of the Directors' and Auditors' thereon; to appoint a Director in place of Dr. Umang Alkesh Gosalia who retires by rotation and being eligible, offers himself for re-appointment; and to consider any other matter thereof. Announcement • Aug 07
Parmax Pharma Limited to Report Q1, 2023 Results on Aug 11, 2022 Parmax Pharma Limited announced that they will report Q1, 2023 results on Aug 11, 2022 Announcement • May 24
Parmax Pharma Limited to Report Q4, 2022 Results on May 30, 2022 Parmax Pharma Limited announced that they will report Q4, 2022 results on May 30, 2022 Announcement • Feb 08
Parmax Pharma Limited to Report Q3, 2022 Results on Feb 14, 2022 Parmax Pharma Limited announced that they will report Q3, 2022 results on Feb 14, 2022 Executive Departure • Oct 03
Independent Director Asha Daftary has left the company On the 24th of September, Asha Daftary's tenure as Independent Director ended after 5.6 years in the role. We don't have any record of a personal shareholding under Asha's name. A total of 3 executives have left over the last 12 months. Is New 90 Day High Low • Mar 09
New 90-day high: ₹34.00 The company is up 5.0% from its price of ₹32.45 on 09 December 2020. The Indian market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is flat over the same period. Executive Departure • Feb 10
MD & Executive Director has left the company On the 8th of February, Alkesh Gopani's tenure in the role of MD & Executive Director ended. As of September 2020, Alkesh personally held 289.21k shares (₹12m worth at the time). A total of 2 executives have left over the last 12 months. Is New 90 Day High Low • Jan 11
New 90-day low: ₹26.05 The company is down 39% from its price of ₹42.80 on 09 October 2020. The Indian market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period. Is New 90 Day High Low • Dec 22
New 90-day low: ₹29.00 The company is down 34% from its price of ₹43.95 on 23 September 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Is New 90 Day High Low • Nov 25
New 90-day low: ₹32.60 The company is down 24% from its price of ₹43.10 on 27 August 2020. The Indian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period. Announcement • Aug 26
Parmax Pharma Limited Announces Temporary Closure of its Manufacturing Unit Parmax Pharma Limited announced that as per directives of conditional order issued by the Deputy Collector and Sub Divisional Magistrate Rajkot City -2, the Company has temporarily closed its production in the unit, till the subsequent order of the Competent Authority in this regard. Announcement • Jul 26
Parmax Pharma Limited to Report Fiscal Year 2020 Results on Jul 30, 2020 Parmax Pharma Limited announced that they will report fiscal year 2020 results on Jul 30, 2020 
